368 related articles for article (PubMed ID: 18027349)
1. Human cytomegalovirus DNA replication: antiviral targets and drugs.
Mercorelli B; Sinigalia E; Loregian A; Palù G
Rev Med Virol; 2008; 18(3):177-210. PubMed ID: 18027349
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitors of human CMV.
Andrei G; De Clercq E; Snoeck R
Curr Opin Investig Drugs; 2008 Feb; 9(2):132-45. PubMed ID: 18246516
[TBL] [Abstract][Full Text] [Related]
3. Antiviral drugs for cytomegalovirus diseases.
Biron KK
Antiviral Res; 2006 Sep; 71(2-3):154-63. PubMed ID: 16765457
[TBL] [Abstract][Full Text] [Related]
4. Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
Lischka P; Zimmermann H
Curr Opin Pharmacol; 2008 Oct; 8(5):541-8. PubMed ID: 18662804
[TBL] [Abstract][Full Text] [Related]
5. Drug targets in cytomegalovirus infection.
Andrei G; De Clercq E; Snoeck R
Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
[TBL] [Abstract][Full Text] [Related]
6. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.
Kaptein SJ; Efferth T; Leis M; Rechter S; Auerochs S; Kalmer M; Bruggeman CA; Vink C; Stamminger T; Marschall M
Antiviral Res; 2006 Feb; 69(2):60-9. PubMed ID: 16325931
[TBL] [Abstract][Full Text] [Related]
7. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
8. Recent strategies in the development of new human cytomegalovirus inhibitors.
Martinez A; Castro A; Gil C; Perez C
Med Res Rev; 2001 May; 21(3):227-44. PubMed ID: 11301412
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ganciclovir-resistant human cytomegalovirus infection.
Grossi P; Baldanti F
J Nephrol; 1997; 10(3):146-51. PubMed ID: 9238622
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus: challenges, opportunities and new drug development.
Field AK
Antivir Chem Chemother; 1999 Sep; 10(5):219-32. PubMed ID: 10574177
[TBL] [Abstract][Full Text] [Related]
11. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
12. Design of translactam HCMV protease inhibitors as potent antivirals.
Borthwick AD
Med Res Rev; 2005 Jul; 25(4):427-52. PubMed ID: 15789440
[TBL] [Abstract][Full Text] [Related]
13. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.
Baldanti F; Gerna G
J Antimicrob Chemother; 2003 Sep; 52(3):324-30. PubMed ID: 12888590
[TBL] [Abstract][Full Text] [Related]
14. Antiviral treatment of cytomegalovirus infection: an update.
Härter G; Michel D
Expert Opin Pharmacother; 2012 Apr; 13(5):623-7. PubMed ID: 22299626
[TBL] [Abstract][Full Text] [Related]
15. [Cytomegaloviruses--clinical aspects and therapy].
Hamprecht K; Jahn G
Ther Umsch; 1994 Aug; 51(8):551-7. PubMed ID: 7940412
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection in immunocompetent and immunocompromised individuals--a review.
Vancíková Z; Dvorák P
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):179-87. PubMed ID: 12476798
[TBL] [Abstract][Full Text] [Related]
17. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation.
Baldanti F; Lilleri D; Gerna G
Hematol Oncol; 2008 Sep; 26(3):123-30. PubMed ID: 18386849
[TBL] [Abstract][Full Text] [Related]
18. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR.
Schnepf N; Boiteau N; Petit F; Alain S; Sanson-Le Pors MJ; Mazeron MC
Antiviral Res; 2009 Jan; 81(1):64-7. PubMed ID: 18992772
[TBL] [Abstract][Full Text] [Related]
19. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections.
Kern ER
Antiviral Res; 2006 Sep; 71(2-3):164-71. PubMed ID: 16828175
[TBL] [Abstract][Full Text] [Related]
20. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
